Supernus Pharmaceuticals SUPN Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's investment proceeds?
- Supernus Pharmaceuticals (SUPN) reported investment proceeds of $59.22M in Q1 2026.
- How has Supernus Pharmaceuticals's investment proceeds changed year-over-year?
- Supernus Pharmaceuticals's investment proceeds decreased by 62.1% year-over-year, from $156.2M to $59.22M.
- What is the long-term trend for Supernus Pharmaceuticals's investment proceeds?
- Over 4 years (2021 to 2025), Supernus Pharmaceuticals's investment proceeds has grown at a 9.9% compound annual growth rate (CAGR), from $530.51M to $774.48M.
- What does investment proceeds mean?
- Cash received from sales, maturities, and redemptions of investment securities across all categories.